nach oben

Erschienen in:

10.02.2020 | Brief Report

High serum levels of periostin are associated with a poor survival in breast cancer

verfasst von: Tilman D. Rachner, Andy Göbel, Oliver Hoffmann, Kati Erdmann, Sabine Kasimir-Bauer, Dorit Breining, Rainer Kimmig, Lorenz C. Hofbauer, Ann-Kathrin Bittner

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Periostin is a secreted extracellular matrix protein, which was originally described in osteoblasts. It supports osteoblastic differentiation and bone formation and has been implicated in the pathogenesis of several human malignancies, including breast cancer. However, little is known about the prognostic value of serum periostin levels in breast cancer.

Methods

In this study, we analyzed serum levels of periostin in a cohort of 509 primary, non-metastatic breast cancer patients. Disseminated tumor cell (DTC) status was determined using bone marrow aspirates obtained from the anterior iliac crests. Periostin levels were stratified according to several clinical parameters and Pearson correlation analyses were performed. Kaplan–Meier survival curves were assessed by using the log-rank (Mantel–Cox) test. To identify prognostic factors, multivariate Cox regression analyses were used.

Results

Mean serum levels of periostin were 505 ± 179 pmol/l. In older patients (> 60 years), periostin serum levels were significantly increased compared to younger patients (540 ± 184 pmol/l vs. 469 ± 167 pmol/l; p < 0.0001) and age was positively correlated with periostin expression (p < 0.0001). When stratifying the cohort according to periostin serum concentrations, the overall and breast cancer-specific mortality were significantly higher in those patients with high serum periostin (above median) compared to those with low periostin during a mean follow-up of 8.5 years (17.7% vs. 11.4% breast cancer-specific death; p = 0.03; hazard ratio 1.65). Periostin was confirmed to be an independent prognostic marker for breast cancer-specific survival (p = 0.017; hazard ratio 1.79). No significant differences in serum periostin were observed when stratifying the patients according to their DTC status.

Conclusions

Our findings emphasize the relevance of periostin in breast cancer and reveal serum periostin as a potential marker for disease prediction, independent on the presence of micrometastases.

Nur mit Berechtigung zugänglich

Takeshita S, Kikuno R, Tezuka K, Amann E (1993) Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem J 294:271–278PubMedPubMedCentral

Horiuchi K, Amizuka N, Takeshita S, Takamatsu H, Katsuura M, Ozawa H, Toyama Y, Bonewald LF, Kudo A (1999) Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor. J Bone Miner Res 14:1239–1249PubMed

Bonnet N, Garnero P, Ferrari S (2016) Periostin action in bone. Mol Cell Endocrinol 432:75–82PubMed

Kruzynska-frejtag A, Machnicki M, Rogers R, Markwald RR, Conway SJ (2001) Periostin (an osteoblast-specific factor ) is expressed within the embryonic mouse heart during valve formation. Mech Dev 103:183–188PubMed

Yoshiba N, Yoshiba K, Hosoya A, Saito M, Yokoi T, Okiji T, Amizuka N, Ozawa H (2007) Association of TIMP-2 with extracellular matrix exposed to mechanical stress and its co-distribution with periostin during mouse mandible development. Cell Tissue Res 330:133–145PubMed

Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr H, Delaloye J, Huelsken J (2012) Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 481:85–91

Liu AY, Zheng H, Ouyang G (2014) Periostin, a multifunctional matricellular protein in inflammatory and tumor microenvironments. Matrix Biol 37:150–156PubMed

Kudo A (2011) Periostin in fibrillogenesis for tissue regeneration: periostin actions inside and outside the cell. Cell Mol Life Sci 68:3201–3207PubMedPubMedCentral

Kudo A, Kii I (2018) Periostin function in communication with extracellular matrices. J Cell Commun Signal 12:301–308PubMed

10.

Graja A, Garcia-Carrizo F, Jank AM, Gohlke S, Ambrosi TH, Jonas W, Ussar S, Kern M, Schürmann A, Aleksandrova K, Blüher M, Schulz TJ (2018) Loss of periostin occurs in aging adipose tissue of mice and its genetic ablation impairs adipose tissue lipid metabolism. Aging Cell 17:1–13

11.

Rios H, Koushik SV, Wang H, Wang J, Zhou H-M, Lindsley A, Rogers R, Chen Z, Maeda M, Kruzynska-Frejtag A, Feng JQ, Conway SJ (2005) Periostin null mice exhibit dwarfism, incisor enamel defects, and an early-onset periodontal disease-like phenotype. Mol Cell Biol 25:11131–11144PubMedPubMedCentral

12.

Bonnet N, Standley KN, Bianchi EN, Stadelmann V, Foti M, Conway SJ, Ferrari SL (2009) The matricellular protein periostin is required for sost inhibition and the anabolic response to mechanical loading and physical activity. J Biol Chem 284:35939–35950PubMedPubMedCentral

13.

Conway SJ, Izuhara K, Kudo Y, Litvin J, Markwald R, Ouyang G, Arron JR, Holweg CTJ, Kudo A (2014) The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci 71:1279–1288PubMed

14.

Bonnet N, Gineyts E, Ammann P, Conway SJ, Garnero P, Ferrari S (2013) Periostin deficiency increases bone damage and impairs injury response to fatigue loading in adult mice. PLoS ONE 8:1–15

15.

Ruan K, Bao S, Ouyang G (2009) The multifaceted role of periostin in tumorigenesis. Cell Mol Life Sci 66:2219–2230PubMed

16.

Masuoka M, Shiraishi H, Ohta S, Suzuki S, Arima K, Aoki S, Toda S, Inagaki N, Kurihara Y, Hayashida S, Takeuchi S, Koike K, Ono J, Noshiro H, Furue M, Conway SJ, Narisawa Y, Izuhara K (2012) Periostin promotes chronic allergic inflammation in response to Th2 cytokines. J Clin Investig 122:2590–2600PubMed

17.

Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, Mosesova S, Eisner MD, Bohen SP, Matthews JG (2011) Lebrikizumab treatment in adults with asthma. N Engl J Med 365:1088–1098PubMed

18.

Nishiyama T, Kii I, Kashima TG, Kikuchi Y, Ohazama A, Shimazaki M, Fukayama M, Kudo A (2011) Delayed re-epithelialization in periostin-deficient mice during cutaneous wound healing. PLoS ONE 6:1–10

19.

Shiraishi H, Masuoka M, Ohta S, Suzuki S, Arima K, Taniguchi K, Aoki S, Toda S, Yoshimoto T, Inagaki N, Conway SJ, Narisawa Y, Izuhara K (2012) Periostin contributes to the pathogenesis of atopic dermatitis by inducing TSLP production from keratinocytes. Allergol Int 61:563–572PubMed

20.

Takayama G, Arima K, Kanaji T, Toda S, Tanaka H, Shoji S, McKenzie ANJ, Nagai H, Hotokebuchi T, Izuhara K (2006) Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 118:98–104PubMed

21.

González-González L, Alonso J (2018) Periostin: a matricellular protein with multiple functions in cancer development and progression. Front Oncol 8:1–15

22.

Morra L, Moch H (2011) Periostin expression and epithelial-mesenchymal transition in cancer : a review and an update. Virchows Arch 459:465–475PubMedPubMedCentral

23.

Venning FA, Wullkopf L, Erler JT (2015) Targeting ECM disrupts cancer progression. Front Oncol 5:1–15

24.

Shao R, Bao S, Bai X, Blanchette C, Anderson RM, Dang T, Gishizky ML, Marks JR, Wang X-F (2004) Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol Cell Biol 24:3992–4003PubMedPubMedCentral

25.

Li C, Xu J, Wang QI, Geng S (2018) Prognostic value of periostin in early-stage breast cancer treated with conserving surgery and radiotherapy. Oncol Lett 15:8072–8078PubMedPubMedCentral

26.

Lee YJ, Kim IS, Park SA, Kim Y, Lee JE, Noh DY, Kim KT, Ryu SH, Suh PG (2013) Periostin-binding DNA aptamer inhibits breast cancer growth and metastasis. Mol Ther 21:1004–1013PubMedPubMedCentral

27.

Kim G, Lee J, Park M, Yoon J (2017) Epithelial periostin expression is correlated with poor survival in patients with invasive breast carcinoma. PLoS ONE 12:1–14

28.

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235PubMed

29.

Rachner TD, Kasimir-Bauer S, Göbel A, Erdmann K, Hoffmann O, Browne A, Wimberger P, Rauner M, Hofbauer LC, Kimmig R, Bittner A (2018) Prognostic value of RANKL/OPG serum levels and disseminated tumor cells in nonmetastatic breast cancer. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-18-2482 CrossRefPubMed

30.

Kasimir-Bauer S, Reiter K, Aktas B, Bittner AK, Weber S, Keller T, Kimmig R, Hoffmann O (2016) Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake? Sci Rep 6:1–10

31.

Gadermaier E, Tesarz M, Suciu AAM, Wallwitz J, Berg G, Himmler G (2018) Characterization of a sandwich ELISA for the quantification of all human periostin isoforms. J Clin Lab Anal 32:1–10

32.

Janni W, Vogl FD, Wiedswang G, Synnestvedt M, Fehm T, Juckstock J, Borgen E, Rack B, Braun S, Sommer H, Solomayer E, Pantel K, Nesland J, Friese K, Naume B (2011) Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse–a European pooled analysis. Clin Cancer Res 17:2967–2976PubMed

33.

Hartkopf AD, Taran F-A, Wallwiener M, Hahn M, Becker S, Solomayer E-F, Brucker SY, Fehm TN, Wallwiener D (2014) Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients—results from a large single-centre analysis. Eur J Cancer 50:2550–2559PubMed

34.

Hartkopf AD, Wallwiener M, Fehm TN, Hahn M, Walter CB, Gruber I, Brucker SY, Taran FA (2015) Disseminated tumor cells from the bone marrow of patients with nonmetastatic primary breast cancer are predictive of locoregional relapse. Ann Oncol 26:1155–1160PubMed

35.

Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga J-Y, Marth C, Oruzio D, Wiedswang G, Solomayer E-F, Kundt G, Strobl B, Fehm T, Wong GYC, Bliss J, Vincent-Salomon A, Pantel K (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353:793–802PubMed

36.

Ratajczak-Wielgomas K, Grzegrzolka J, Piotrowska A, Gomulkiewicz A, Witkiewicz W, Dziegiel P (2016) Periostin expression in cancer-associated fibroblasts of invasive ductal breast carcinoma. Oncol Rep 36:2745–2754PubMed

37.

Xu D, Xu H, Ren Y, Liu C, Wang X, Zhang H, Lu P (2012) Cancer stem cell-related gene periostin: a novel prognostic marker for breast cancer. PLoS ONE 7:1–10

38.

Lambert AW, Wong CK, Ozturk S, Papageorgis P, Raghunathan R, Alekseyev Y, Gower AC, Reinhard BM, Abdolmaleky HM, Thiagalingam S (2015) Tumor cell-derived periostin regulates cytokines that maintain breast cancer stem cells. Mol Cancer Res 14:103–113PubMedPubMedCentral

39.

Nuzzo PV, Rubagotti A, Argellati F, Di Meglio A, Zanardi E, Zinoli L, Comite P, Mussap M, Boccardo F (2015) Prognostic value of preoperative serum levels of periostin (PN) in early breast cancer (BCa). Int J Mol Sci 16:17181–17192PubMedPubMedCentral

40.

Rousseau JC, Sornay-Rendu E, Bertholon C, Chapurlat R, Garnero P (2014) Serum periostin is associated with fracture risk in postmenopausal women: a 7-year prospective analysis of the OFELY study. J Clin Endocrinol Metab 99:2533–2539PubMed

41.

Takahashi K, Meguro K, Kawashima H, Kashiwakuma D, Kagami S, Ohta S, Ono J, Izuhara K, Iwamoto I (2019) Serum periostin levels serve as a biomarker for both eosinophilic airway inflammation and fixed airflow limitation in well-controlled asthmatics. J Asthma 4(56):236–243

42.

Lu Y, Liu X, Jiao Y, Xiong X, Wang E, Wang X, Zhang Z, Zhang H, Pan L, Guan Y, Cai D, Ning G, Li X (2014) Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα. J Clin Investig 1(124):3501–3513

43.

Gineyts E, Bonnet N, Bertholon C, Millet M, Pagnon-Minot A, Borel O, Geraci S, Bonnelye E, Croset M, Suhail A, Truica C, Lamparella N, Leitzel K, Hartmann D, Chapurlat R, Lipton A, Garnero P, Ferrari S, Clézardin P, Rousseau JC (2018) The C-terminal intact forms of periostin (iPTN) are surrogate markers for osteolytic lesions in experimental breast cancer bone metastasis. Calcif Tissue Int 103:567–580PubMed

44.

Sasaki H, Yu C-Y, Dai M, Tam C, Loda M, Auclair D, Chen LB, Elias A (2003) Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer. Breast Cancer Res Treat 77:245–252PubMed

45.

Puglisi F, Puppin C, Pegolo E, Andreetta C, Pascoletti G, D’Aurizio F, Pandolfi M, Fasola G, Piga A, Damante G, Di Loreto C (2008) Expression of periostin in human breast cancer. J Clin Pathol 61:494–498PubMed

46.

Nakazawa Y, Taniyama Y, Sanada F, Morishita R (2018) Periostin blockade overcomes chemoresistance via restricting the expansion of mesenchymal tumor subpopulations in breast cancer. Sci Rep 8:1–14

47.

Hu W-W, Chen P-C, Chen J-M, Wu Y-M, Liu P-Y, Lu C-H, Lin Y-F, Tang C-H, Chao C-C (2017) Periostin promotes epithelial-mesenchymal transition via the MAPK/miR-381 axis in lung cancer. Oncotarget 8:62248–62260PubMedPubMedCentral

48.

Hu Q, Tong S, Zhao X, Ding W, Gou Y, Xu K, Sun C, Xia G (2015) Periostin mediates TGF-β-induced epithelial mesenchymal transition in prostate cancer cells. Cell Physiol Biochem 36:799–809PubMed

49.

Mino M, Kanno K, Okimoto K, Sugiyama A, Kishikawa N, Kobayashi T, Ono J, Izuhara K, Kobayashi T, Ohdan H, Tazuma S (2017) Periostin promotes malignant potential by induction of epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatol Commun 1:1099–1109PubMedPubMedCentral

50.

Jang MH, Kim HJ, Kim EJ, Chung YR, Park SY (2015) Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome. Hum Pathol 46:1267–1274PubMed

Titel: High serum levels of periostin are associated with a poor survival in breast cancer
verfasst von: Tilman D. Rachner
Andy Göbel
Oliver Hoffmann
Kati Erdmann
Sabine Kasimir-Bauer
Dorit Breining
Rainer Kimmig
Lorenz C. Hofbauer
Ann-Kathrin Bittner
Publikationsdatum: 10.02.2020
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 2/2020
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05570-0

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

High serum levels of periostin are associated with a poor survival in breast cancer

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Multiparametric radiomics methods for breast cancer tissue characterization using radiological imaging

Male breast cancer: a closer look at patient and tumor characteristics and factors that affect survival using the National Cancer Database

Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers

GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models

The prognostic value of HER2 status and efficacy of anti-HER2 therapy in patients with HR-positive mucinous breast cancer: a nationwide study from the Korean Breast Cancer Society

pHLIP(Var7)-P1AP suppresses tumor cell proliferation in MDA-MB-231 triple-negative breast cancer by targeting protease activated receptor 1

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie